BCRX

Business Context and Reporting Period

Company: BioCryst Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: BioCryst is a biotechnology company focused on structure-based drug design, primarily developing peramivir (an influenza neuraminidase inhibitor) and PNP inhibitors (forodesine and BCX4208). The company relies heavily on government contracts (HHS) and collaborative agreements (Shionogi, Mundipharma) for funding and revenue.

Key Financial Metrics

Note: The company reported no product sales or royalties in Q1 2011. Revenue was derived entirely from collaborative and research and development arrangements.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by $20.7 million (80%) compared to Q1 2010. This was primarily due to the absence of a $7.0 million milestone payment from Shionogi (received in Q1 2010) and a $6.4 million sale of peramivir API to collaborators in the prior year. Additionally, HHS contract revenue decreased by $6.0 million due to study realignments and a $3.6 million reduction in estimated revenue from a CRO cost reconciliation.
• Expense Reduction: Research and Development (R&D) expenses decreased by $12.0 million to $12.9 million, driven by lower peramivir and forodesine development costs and the absence of $6.3 million in API manufacturing costs recorded in Q1 2010.
• Increased Net Loss: Despite lower operating expenses, the net loss widened significantly to $13.0 million. This was driven by a $1.3 million mark-to-market loss on a new foreign currency hedge agreement and $0.3 million in interest expense on new debt.
• Liquidity Improvement: Cash and cash equivalents increased by $17.7 million during the quarter, primarily due to net proceeds of approximately $23.0 million from a royalty monetization transaction.

Guidance, Outlook, and Material Events

Royalty Monetization Transaction

On March 9, 2011, the company completed a $30.0 million financing transaction via a wholly-owned subsidiary (JPR Royalty Sub LLC). The subsidiary issued non-recourse notes secured by future royalty and milestone payments from Shionogi. The company received net proceeds of approximately $23.0 million after transaction costs and the establishment of a $3.0 million interest reserve.

Foreign Currency Hedge

To mitigate currency risk associated with the Shionogi royalties (paid in Japanese Yen), the company entered into a Currency Hedge Agreement. This agreement resulted in a $1.3 million loss in Q1 2011 due to mark-to-market adjustments and required an initial collateral posting of $1.9 million.

HHS Contract Modification

On February 24, 2011, the U.S. Department of Health and Human Services (HHS) awarded a $55.0 million contract modification to fund the completion of Phase 3 development of i.v. peramivir. This extends the contract through December 31, 2013. The company plans to modify its ongoing Study 301 to increase enrollment to 600 subjects and focus on patients not treated with neuraminidase inhibitors.

Clinical Updates

• Peramivir: Study 303 results showed peramivir was safe and well-tolerated. Study 301 is ongoing with modified protocols.
• BCX4208 (Gout): Phase 2 studies demonstrated significant reduction in serum uric acid levels. A Phase 2b study as add-on therapy was initiated in December 2010.
• Forodesine: The company announced it does not plan to conduct additional U.S. studies or file an NDA absent a partner. A dispute with partner Mundipharma regarding development costs is ongoing, with potential exposure estimated at $2.3 million.

Liquidity Outlook

Management expects cash use in 2011 to be approximately $35.0 million. With current resources and expected HHS funding, the company believes it has sufficient capital to fund operations for at least the next 24 months.

Investor Verification Checklist

• Royalty Monetization Terms: Verify the specific covenants and "Event of Default" triggers in the PhaRMA Notes indenture, particularly regarding interest shortfalls and the company's obligation to contribute capital.
• Currency Hedge Exposure: Assess the potential future cash outflows required for the Currency Hedge Agreement premiums (up to $2.0 million annually from 2014-2020) and collateral calls if the Yen strengthens against the Dollar.
• HHS Contract Performance: Monitor the progress of the modified Study 301 enrollment and the company's ability to meet HHS milestones to ensure continued reimbursement.
• Mundipharma Dispute: Track the resolution of the dispute regarding forodesine development costs, which could result in a liability of approximately $2.3 million.
• Forodesine Strategy: Confirm if a U.S. partner is secured for forodesine; without one, the asset may have limited future value to the company.